Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: r...
Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours
About this item
Full title
Author / Creator
Yuan, Peng , Shentu, Jianzhong , Xu, Jianming , Burke, Wendy , Hsu, Kate , Learoyd, Maria , Zhu, Min and Xu, Binghe
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Purpose
Chinese patients have been enrolled in multiple Phase III trials of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza); however, the pharmacokinetic (PK) profile of olaparib has not been investigated in this population. This two-part, open-label Phase I study was, therefore, carried out to determine the PK and safety pr...
Alternative Titles
Full title
Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2193420624
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2193420624
Other Identifiers
ISSN
0344-5704
E-ISSN
1432-0843
DOI
10.1007/s00280-019-03799-1
